CAR-NK细胞在肿瘤免疫学治疗中的应用  

Progresses of the application of CAR-NK cell in tumor immunotherapy

作　　者：刘欣[1] 赵娜[1] LIU Xin;ZHAO Na(Tianjin Institute of General Surgery&Department of General Surgery,Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院普通外科天津市普通外科研究所,300052

出　　处：《免疫学杂志》2020年第4期358-363,共6页Immunological Journal

基　　金：国家自然科学基金青年项目(81702410);天津市自然科学基金青年项目(17JCQNJC11100);天津医科大学科学基金青年项目(2016KYZQ02)。

摘　　要：嵌合抗原受体(chimeric antigen receptor,CAR)是为了使免疫效应细胞能够识别肿瘤表面抗原并以HLA不受限制的方式杀死靶细胞而开发的。自然杀伤(natural killer,NK)细胞是固有免疫系统的重要组成部分,在肿瘤免疫治疗中以非特异性的方式杀死肿瘤细胞。随着CAR-T细胞疗法和过继细胞疗法在肿瘤免疫治疗中取得成功,NK细胞因其无需预先致敏并且不会导致移植物抗宿主病,在CAR细胞疗法中受到越来越多的关注。近几年有很多对CAR-NK细胞疗法靶点的临床前研究,在肿瘤治疗中显示出很好的疗效。本文就近几年研究多的CAR-NK细胞疗法靶点的研究现状及其应用做一综述。Chimeric antigen receptor(CAR)has developed to enable immune effector cells to recognize tumor surface antigens and kill target cells in an unrestricted manner by HLA.Natural killer(NK)cells are an important part of the innate immune system,killing tumor cells in a non-specific way in tumor immunity.With the success of CAR-T cell therapy and adoptive cell therapy in cancer immunotherapy,NK cells have attracted more and more attention because they do not require pre-sensitization and do not cause graft-versus-host disease.In recent years,there have been many preclinical studies on the therapeutic targets of CAR-NK cells,which have shown good therapeutic effects in cancer therapy.This article reviews the research status and application of CAR-NK therapy targets in recent years.

关 键 词：CAR-NK 肿瘤免疫治疗 CD19 HER2 EGFR 

分 类 号：R392.4[医药卫生—免疫学]